医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

in China

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

バイオテクノロジーヘルスケアヘルス一般臨床試験製薬　 TimeLine: a Novel Nutraceutical for Menopause Aptorum Group Launches NativusWell in China

2023年03月02日

Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China

Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China

バイオテクノロジーヘルスケア製薬　 TimeLine: in China Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta

2023年01月31日

InnoCare Announces First Patient Dosed in Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China

InnoCare Announces First Patient Dosed in Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: in China InnoCare Announces First Patient Dosed in Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP

2022年06月22日

D＆D Pharmatech Announces Agreement with Salubris Pharmaceuticals for Licensing and Development of DD01 in China

D＆D Pharmatech Announces Agreement with Salubris Pharmaceuticals for Licensing and Development of DD01 in China

その他ヘルスバイオテクノロジーヘルスケア糖尿病製薬　 TimeLine: D＆D Pharmatech Announces Agreement with Salubris Pharmaceuticals for Licensing and Development of DD in China

2021年09月27日

Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum™ in China

Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum™ in China

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: in China Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum

2021年07月20日

Simulations Plus Enters Agreement with Distributor in China

Simulations Plus Enters Agreement with Distributor in China

バイオテクノロジーヘルスケア製薬　 TimeLine: in China Simulations Plus Enters Agreement with Distributor

2021年02月02日

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China

AIDS ヘルスケア臨床試験製薬　 TimeLine: EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT in China Siltuximab for Injection

2021年01月25日

Genetron Health Announces Exclusive Strategic Partnership with Sino Biopharm Subsidiary for HCCscreen™ in China

Genetron Health Announces Exclusive Strategic Partnership with Sino Biopharm Subsidiary for HCCscreen™ in China

バイオテクノロジーヘルスケア感染症腫瘍学製薬　 TimeLine: Genetron Health Announces Exclusive Strategic Partnership with Sino Biopharm Subsidiary for HCCscreen in China

2021年01月06日

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA®▼ (Dinutuximab Beta) in China

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA®▼ (Dinutuximab Beta) in China

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: dinutuximab beta EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA in China

2020年11月09日

Gelesis Announces Partnership for Commercial Launch of Plenity® in China

Gelesis Announces Partnership for Commercial Launch of Plenity® in China

その他ヘルスバイオテクノロジーヘルスケア糖尿病臨床試験製薬　 TimeLine: Gelesis Announces Partnership for Commercial Launch of Plenity in China

2020年06月18日